

Approved



Eswatini
Country Operational Plan
FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		1,074,929		1,074,929	0	1,074,929
USAID		31,872,548	6,900,000	38,772,548	102,540	38,875,088
DOD		1,615,939		1,615,939	214,061	1,830,000
PC		920,786		920,786	219,214	1,140,000
HHS/CDC	487,500	23,343,696		23,831,196	0	23,831,196
State/AF		40,571		40,571	0	40,571
Total	487,500	58,868,469	6,900,000	66,255,969	535,815	66,791,784

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						Total
	State	DOD	HHS/CDC	PC	State/AF	USAID	
CIRC	2,378	141,878	563,392	0	0	5,490,729	6,198,377
HBHC	124,481	171,888	7,878,459	7,500	40,571	5,242,145	13,465,044
HKID	22,590	0	0	45,000	0	6,956,760	7,024,350
HLAB	0	168,122	316,024	0	0	0	484,146
HMBL	0	0	0	0	0	0	0
HMIN	0	0	0	0	0	0	0
HTXD	15,694	0	0	0	0	1,354,799	1,370,493
HTXS	174,631	171,887	6,223,308	0	0	5,363,687	11,933,513
HVAB	0	0	0	0	0	995,555	995,555
HVCT	51,126	167,694	2,846,206	0	0	2,582,604	5,647,630
HVMS	500,930	4,194	1,096,300	845,786		1,220,219	3,667,429
HVOP	36,739	146,072	0	22,500	0	3,335,797	3,541,108

Approved



HVSI	29,012	304,194	1,307,392	0	0	1,669,724	3,310,322
HVTB	18,665	167,694	1,482,683	0	0	708,632	2,377,674
IDUP	0	0	0	0	0	0	0
MTCT	24,731	0	338,822	0	0	801,730	1,165,283
OHSS	27,321	172,316	670,486	0	0	971,127	1,841,250
PDCS	26,039	0	830,347	0	0	1,629,578	2,485,964
PDTX	20,592	0	277,777	0	0	449,462	747,831
	1,074,929	1,615,939	23,831,196	920,786	40,571	38,772,548	66,255,969



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	12,505,927
HKID	6,638,634
HVTB	2,161,912
PDCS	2,316,387
Total Technical Area Planned Funding:	23,622,860

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	447,249
HVSI	2,489,235
OHSS	1,630,441
Total Technical Area Planned Funding:	4,566,925

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	6,145,663
HMBL	0
HMIN	0
HVAB	995,555
HVCT	5,449,397
HVOP	3,460,013
IDUP	0
MTCT	1,012,891
Total Technical Area Planned Funding:	17,063,519

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	1,306,218
HTXS	10,319,608
PDTX	622,054
Total Technical Area Planned Funding:	12,247,880



Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	92 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	22,966
	Number of new ANC and L&D clients	24,957
	By Age (Denominator): 10-14	230
	By Age (Denominator): <15-19	3,717
	By Age (Denominator): 20-24	7,150
	By Number of known positives: 10-14	40
	By Number of known positives: 15-19	851
	By Number of known positives: 20-24	1,624
	By Number of new positives: 10-14	13
	By Number of new positives: 15-19	306
	By Number of new positives: 20-24	402
	By Number of new negative: 10-14	159
	By Number of new negative: 15-19	2,341
	By Number of new negative: 20-24	3,164
	By Age (Numerator): 10-14	229
	By Age (Numerator): 15-19	3,525
By Age (Numerator): 20-24	6,506	



PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	7,415
PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	3,723
PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,491
PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	231
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	1,620
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	4,699
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	628
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	841
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	3,173
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	412
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	558
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Negative	1,881
PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Positive	243



	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	36
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	309
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	25
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	8,268
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	4,441
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,687
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	404
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	94 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	926
	Number of new ANC and L&D clients	988
	By Age (Denominator): 10-14	8
	By Age (Denominator): 15-19	138
	By Age (Denominator): 20-24	289
	By known positives: 15-19	24
	By known positives: 20-24	68
	By new positives: 15-19	4



	By new positives: 20-24	19
	By new negatives: 15-19	50
	By new negatives: 20-24	137
	By Age (Numerator): : 15-19	89
	By Age (Numerator): 20-24	227
	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	291
	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	153
	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	100
	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	9
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Known at Entry Positive	69
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Negative	193
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Positive	25
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Known at Entry Positive	34
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Newly Identified Negative	182
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Newly Identified Positive	20
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Known at Entry Positive	21



	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Newly Identified Negative	50
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Newly Identified Positive	1
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 40-49, Female, Newly Identified Negative	12
	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	293
	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	241
	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	75
	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	13
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	32 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	7,365
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	22,966
	New on ART	3,407
	Already on ART at beginning of current pregnancy	3,958
PMTCT_ART_TA	PMTCT_ART_TA Percentage of	31 %



	HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	287
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	926
	New on ART	141
	Already on ART at beginning of current pregnancy	146
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	31,092
	By Age: 10-14	7,383
	By Age: 15-19	12,327
	By Age: 20-24	4,859
	By Age: 25-29	1,887
	By Age: 50+	129
	By circumcision technique: Surgical VMMC	31,587
	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	3,077
	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,299
	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	645



PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	3,268
	Male 15-19	187
	Male 20-24	217
	Male 50+	5
	Female 15-19	300
	Female 20-24	338
	Female 50+	15
	FSW	133
	MSM	133
	TG	133
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	349
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	242
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	331
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	222
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	369
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	222
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	337
	PrEP_NEW_N_DSD_Age_Sex_v2	167



	40-49, Male	
	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	133
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	118,628
	Age/sex: 10-14 Male	454
	Age/sex: 15-19 Male	9,849
	Age/sex: 20-24 Male	16,166
	Age/sex: 50+ Male	469
	Age/sex: 10-14 Female	9,455
	Age/sex: 15-19 Female	15,089
	Age/sex: 20-24 Female	17,500
	Age/sex: 50+ Female	469
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	14,444
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	15,755
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	1,010
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	11,193
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	746
PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	4,818	



	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	538
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	669
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	15,329
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,396
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,933
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,339



	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	552
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	3
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	567
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	4
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	96
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	2
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	58
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	2
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	212
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	3
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	132
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	3
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	68
	Service Delivery Point (Facility) Other PITC: <1, Negative	21



Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,246
Service Delivery Point (Facility) Other PITC: 1-9, Positive	17
Service Delivery Point (Facility) Pediatric : <5 Negative	1,356
Service Delivery Point (Facility) Pediatric : <5 Positive	19
Service Delivery Point (Facility) TB: 50+, Female, Negative	7
Service Delivery Point (Facility) TB: 50+, Female, Positive	6
Service Delivery Point (Facility) TB: 50+, Male, Negative	6
Service Delivery Point (Facility) TB: 50+, Male, Positive	6
Service Delivery Point (Facility) Index: 10-14, Female, Negative	12
Service Delivery Point (Facility) Index: 10-14, Male, Negative	11
Service Delivery Point (Facility) Index: 15-19, Female, Negative	11
Service Delivery Point (Facility) Index: 15-19, Female, Positive	1
Service Delivery Point (Facility) Index: 15-19, Male, Negative	8
Service Delivery Point (Facility) Index: 20-24, Female, Negative	33
Service Delivery Point (Facility) Index: 20-24, Female, Positive	5
Service Delivery Point (Facility) Index: 20-24, Male, Negative	20
Service Delivery Point (Facility) Index: 20-24, Male, Positive	5



	Service Delivery Point (Facility) Index: 50+, Male, Negative	19
	Service Delivery Point (Facility) Index: 50+, Male, Positive	1
	Service Delivery Point (Facility) Index: 1-9, Negative	27
	Service Delivery Point (Facility) Index: 1-9, Positive	1
	Service Delivery Point (Facility) ANC: 15-19, Negative	107
	Service Delivery Point (Facility) ANC: 15-19, Positive	14
	Service Delivery Point (Facility) ANC: 20-24, Negative	132
	Service Delivery Point (Facility) ANC: 20-24, Positive	25
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	5
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	6
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	6
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	8
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	20
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	12
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	4



	Service Delivery Point (Facility) VCT: 1-9, Negative	16
	Service Delivery Point (Facility) VCT: 1-9, Positive	1
	HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Negative	28
	HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Positive	4
	HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Negative	33
	HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Positive	4
	HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Female, Negative	18
	HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Female, Positive	3
	HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Male, Negative	34
	HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Male, Positive	4
	HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Female, Negative	14
	HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Female, Positive	0
	HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Male, Negative	31
	HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Male, Positive	4
	HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Female, Negative	14
	HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Female, Positive	1
	HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Male, Negative	32



HTS_TST_N_TA_Index_Age_Sex_	4
Result 40-49, Male, Positive	
HTS_TST_N_TA_OtPITC_Age_Sex_	168
Result 25-29, Female, Negative	
HTS_TST_N_TA_OtPITC_Age_Sex_	2
Result 25-29, Female, Positive	
HTS_TST_N_TA_OtPITC_Age_Sex_	214
Result 25-29, Male, Negative	
HTS_TST_N_TA_OtPITC_Age_Sex_	5
Result 25-29, Male, Positive	
HTS_TST_N_TA_OtPITC_Age_Sex_	114
Result 30-34, Female, Negative	
HTS_TST_N_TA_OtPITC_Age_Sex_	2
Result 30-34, Female, Positive	
HTS_TST_N_TA_OtPITC_Age_Sex_	206
Result 30-34, Male, Negative	
HTS_TST_N_TA_OtPITC_Age_Sex_	5
Result 30-34, Male, Positive	
HTS_TST_N_TA_OtPITC_Age_Sex_	103
Result 35-39, Female, Negative	
HTS_TST_N_TA_OtPITC_Age_Sex_	2
Result 35-39, Female, Positive	
HTS_TST_N_TA_OtPITC_Age_Sex_	194
Result 35-39, Male, Negative	
HTS_TST_N_TA_OtPITC_Age_Sex_	4
Result 35-39, Male, Positive	
HTS_TST_N_TA_OtPITC_Age_Sex_	97
Result 40-49, Female, Negative	
HTS_TST_N_TA_OtPITC_Age_Sex_	2
Result 40-49, Female, Positive	
HTS_TST_N_TA_OtPITC_Age_Sex_	152
Result 40-49, Male, Negative	
HTS_TST_N_TA_OtPITC_Age_Sex_	5
Result 40-49, Male, Positive	



	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	132
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	25
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	132
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	25
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	104
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	19
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	24
	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	3
	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	1
	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	1
	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	1
	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	1
	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	17
	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	21
	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	18
	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	15
	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	10



	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Male, Negative	9
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Female, Negative	3
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Male, Negative	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 10-14, Female, Directly-Assisted	11
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 10-14, Female, Unassisted	28
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 10-14, Male, Directly-Assisted	11
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 10-14, Male, Unassisted	12
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 15-19, Female, Directly-Assisted	11
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 15-19, Female, Unassisted	12
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 15-19, Male, Directly-Assisted	39
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 15-19, Male, Unassisted	73
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Female, Directly-Assisted	39
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Female, Unassisted	73
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Male, Directly-Assisted	39	



HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Male, Unassisted	74
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 25-29, Female, Directly-Assisted	39
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 25-29, Female, Unassisted	74
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 25-29, Male, Directly-Assisted	39
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 25-29, Male, Unassisted	74
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Female, Directly-Assisted	39
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Female, Unassisted	74
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Male, Directly-Assisted	39
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Male, Unassisted	74
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Female, Directly-Assisted	39
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Female, Unassisted	74
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Male, Directly-Assisted	39
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Male, Unassisted	74
HTS_SELF_N_TA_Age_Sex_HIVS elfTest 40-49, Female, Directly-Assisted	39



	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	74
	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	39
	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	176
	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Other	321
	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	325
	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	326
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	99 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,093
	Total number of registered new and relapsed TB cases, during the reporting period.	4,116
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	128
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,149



	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	138
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,671
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	133
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,156
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	141
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,676
	TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		49



	Total number of registered new and relapsed TB cases, during the reporting period.	49
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	16
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	23
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	24
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
	Aggregated Age/Sex: Female 15+	16



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
HTS_SELF_DSD	HTS_SELF_N_DSD	1,620
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Directly-Assisted	620
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Unassisted	1,234
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Directly-Assisted	620
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Unassisted	622
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	705
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	742
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	2,099
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	3,500
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	2,109
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Unassisted	3,690
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male,	2,109



	Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	3,640
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	2,119
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	3,740
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	2,114
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	3,690
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	2,109
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	3,640
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	2,109
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	3,711
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	2,109
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	3,551
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	2,104
	HTS_SELF_N_DSD_Age_Sex_HI	3,610



	VSelfTest 35-39, Male, Unassisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	2,099
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	3,530
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	2,104
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	7,036
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	10
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	20
	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	100
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,520
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Other	14,657
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Self	14,766
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Sex Partner	14,998
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	249,171
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	434
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	10



	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	434
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	5
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	73
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	8
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	43
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	4
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	155
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	17
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	100
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	10
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	57
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	7
	Service Delivery Point (Facility) Inpatient: <1, Negative	17
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,089
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	23
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	782
	Service Delivery Point (Community)	392



	Mobile Testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	2,925
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	152
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	404
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	31
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	5,898
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	315
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,408
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	157
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	819
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	69
	Service Delivery Point (Community) Mobile Testing: <1, Negative	19
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	987



	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	8,843
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	178
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	8,841
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	179
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,453
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	105
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,476
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	56
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	5,389
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	248
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,435
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	156
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,627
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	88



Service Delivery Point (Facility) Other PITC: <1, Negative	282
Service Delivery Point (Facility) Other PITC: <1, Positive	6
Service Delivery Point (Facility) Other PITC: 1-9, Negative	15,805
Service Delivery Point (Facility) Other PITC: 1-9, Positive	432
Service Delivery Point (Facility) Pediatric : <5 Negative	39,202
Service Delivery Point (Facility) Pediatric : <5 Positive	815
Service Delivery Point (Facility) TB: 10-14, Female, Negative	8
Service Delivery Point (Facility) TB: 10-14, Female, Positive	4
Service Delivery Point (Facility) TB: 10-14, Male, Negative	5
Service Delivery Point (Facility) TB: 10-14, Male, Positive	5
Service Delivery Point (Facility) TB: 15-19, Female, Negative	4
Service Delivery Point (Facility) TB: 15-19, Female, Positive	4
Service Delivery Point (Facility) TB: 15-19, Male, Negative	5
Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
Service Delivery Point (Facility) TB: 20-24, Female, Negative	42
Service Delivery Point (Facility) TB: 20-24, Female, Positive	18
Service Delivery Point (Facility) TB: 20-24, Male, Negative	111



	Service Delivery Point (Facility) TB: 20-24, Male, Positive	43
	Service Delivery Point (Facility) TB: 50+, Female, Negative	24
	Service Delivery Point (Facility) TB: 50+, Female, Positive	10
	Service Delivery Point (Facility) TB: 50+, Male, Negative	20
	Service Delivery Point (Facility) TB: 50+, Male, Positive	11
	Service Delivery Point (Facility) TB: 1-9, Negative	11
	Service Delivery Point (Facility) TB: 1-9, Positive	6
	Service Delivery Point (Facility) VMC: 10-14, Negative	13,929
	Service Delivery Point (Facility) VMC: 10-14, Positive	407
	Service Delivery Point (Facility) VMC: 15-19, Negative	8,113
	Service Delivery Point (Facility) VMC: 15-19, Positive	233
	Service Delivery Point (Facility) VMC: 20-24, Negative	2,327
	Service Delivery Point (Facility) VMC: 20-24, Positive	74
	Service Delivery Point (Facility) VMC: 50+, Negative	5
	Service Delivery Point (Facility) VMC: 50+, Positive	1
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	392
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	11



Service Delivery Point (Facility) Index: 10-14, Male, Negative	374
Service Delivery Point (Facility) Index: 10-14, Male, Positive	10
Service Delivery Point (Facility) Index: 15-19, Female, Negative	364
Service Delivery Point (Facility) Index: 15-19, Female, Positive	64
Service Delivery Point (Facility) Index: 15-19, Male, Negative	223
Service Delivery Point (Facility) Index: 15-19, Male, Positive	36
Service Delivery Point (Facility) Index: 20-24, Female, Negative	783
Service Delivery Point (Facility) Index: 20-24, Female, Positive	155
Service Delivery Point (Facility) Index: 20-24, Male, Negative	510
Service Delivery Point (Facility) Index: 20-24, Male, Positive	92
Service Delivery Point (Facility) Index: 50+, Male, Negative	426
Service Delivery Point (Facility) Index: 50+, Male, Positive	41
Service Delivery Point (Facility) Index: <1, Negative	8
Service Delivery Point (Facility) Index: 1-9, Negative	956
Service Delivery Point (Facility) Index: 1-9, Positive	40
By Key Population: FSW, Negative	1,697
By Key Population: FSW, Positive	237
By Key Population: MSM, Negative	1,100
By Key Population: MSM, Positive	132



Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	419
Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	16
Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	420
Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	18
Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	430
Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	72
Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	259
Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	43
Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	949
Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	158
Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	604
Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	98
Service Delivery Point (Community) Index Mod: 50+, Male, Negative	516
Service Delivery Point (Community) Index Mod: 50+, Male, Positive	85
Service Delivery Point (Community) Index Mod: <1, Negative	19
Service Delivery Point (Community)	1,049



	Index Mod: 1-9, Negative	
	Service Delivery Point (Community)	40
	Index Mod: 1-9, Positive	
	Service Delivery Point (Facility)	2,679
	ANC: 15-19, Negative	
	Service Delivery Point (Facility)	366
	ANC: 15-19, Positive	
	Service Delivery Point (Facility)	3,300
	ANC: 20-24, Negative	
	Service Delivery Point (Facility)	440
	ANC: 20-24, Positive	
	Service Delivery Point (Facility)	166
	VCT: 10-14, Female, Negative	
	Service Delivery Point (Facility)	4
	VCT: 10-14, Female, Positive	
	Service Delivery Point (Facility)	168
	VCT: 10-14, Male, Negative	
	Service Delivery Point (Facility)	4
	VCT: 10-14, Male, Positive	
	Service Delivery Point (Facility)	348
	VCT: 15-19, Female, Negative	
	Service Delivery Point (Facility)	31
	VCT: 15-19, Female, Positive	
	Service Delivery Point (Facility)	209
	VCT: 15-19, Male, Negative	
	Service Delivery Point (Facility)	12
	VCT: 15-19, Male, Positive	
	Service Delivery Point (Facility)	805
	VCT: 20-24, Female, Negative	
	Service Delivery Point (Facility)	72
	VCT: 20-24, Female, Positive	
	Service Delivery Point (Facility)	491
	VCT: 20-24, Male, Negative	
	Service Delivery Point (Facility)	38



	VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	40
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	5
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	408
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	30
	Service Delivery Point (Facility) VCT: <1, Negative	2
	Service Delivery Point (Facility) VCT: 1-9, Negative	402
	Service Delivery Point (Facility) VCT: 1-9, Positive	19
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	181
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	176
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	264
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	38
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	158
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	22
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	577
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	88
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	367
	Service Delivery Point (Community)	56



VCT Mod: 20-24, Male, Positive	
Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	316
Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	48
Service Delivery Point (Community) VCT Mod: <1, Negative	8
Service Delivery Point (Community) VCT Mod: 1-9, Negative	444
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	668
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	132
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	820
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	162
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	474
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	79
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	850
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	158
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	399
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	74
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	762
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	144
HTS_TST_N_DSD_Index_Age_Sex	360



x_Result 40-49, Female, Negative	
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	60
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	828
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	144
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	128
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	12
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	157
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	15
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	85
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	9
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	157
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	15
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	73
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	8
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	142
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	15
HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	73
HTS_TST_N_DSD_Inpat_Age_Sex	8



	_Result 40-49, Female, Positive	
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	157
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	15
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	5,484
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	264
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Negative	2,872
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Positive	197
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Negative	957
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Positive	89
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Negative	1,447
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Positive	122
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Negative	763
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Positive	73
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Male, Negative	1,336
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Male, Positive	115



	Sex_Result 35-39, Male, Positive	
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 40-49, Female, Negative	585
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 40-49, Female, Positive	49
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 40-49, Male, Negative	1,557
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 40-49, Male, Positive	142
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Female, Negative	777
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Female, Positive	127
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Male, Negative	951
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Male, Positive	160
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Female, Negative	516
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Female, Positive	85
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Male, Negative	951
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Male, Positive	160
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Female, Negative	432



HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	72
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	864
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	141
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	432
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	72
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	951
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	160
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	4,426
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	197
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	5,570
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	238
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	3,040
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	132
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	5,397



HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	238
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	2,670
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	109
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	5,067
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	223
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	2,530
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	109
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	4,084
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	238
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	3,306
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	446
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	3,306
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	446
HTS_TST_N_DSD_PMTCT_Age_	2,512



	Sex_Result 35-39, Female, Negative	
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	326
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	621
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	67
	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	29
	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	16
	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	180
	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	92
	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	33
	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	23
	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	207
	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	109
	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	31
	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	24
	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	156
	HTS_TST_N_DSD_TBC_Age_Sex	72



	_Result 35-39, Male, Positive	
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	32
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	23
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	159
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	71
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	700
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	75
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	819
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	68
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	707
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	78
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	953
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	89
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	590
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	52
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	869
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	98
	HTS_TST_N_DSD_VCT_Age_Sex	458



	_Result 40-49, Female, Negative	
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	32
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	820
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	76
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Negative	472
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Positive	72
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Negative	579
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Positive	88
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Negative	316
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Positive	48
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Male, Negative	579
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Male, Positive	88
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Female, Negative	264
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Female, Positive	39
	HTS_TST_N_DSD_VCTMod_Age_	525



	Sex_Result 35-39, Male, Negative	
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	80
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	264
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	39
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	579
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	88
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	2,588
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	87
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,600
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	66
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	1,247
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	56
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	923
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	23
GEND_GBV_DSD	Number of people receiving post-GBV care	4,644
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,830



	By type of service: Sexual Violence (Post-Rape Care)	1,395
	By PEP service provision (related to sexual violence services provided)	1,348
	<10, Female, Physical and/or Emotional Violence	21
	<10, Female, Sexual Violence (Post-Rape Care)	93
	<10, Male, Physical and/or Emotional Violence	67
	<10, Male, Sexual Violence (Post-Rape Care)	1
	10-14, Female, Physical and/or Emotional Violence	55
	10-14, Female, Sexual Violence (Post-Rape Care)	188
	10-14, Male, Physical and/or Emotional Violence	162
	10-14, Male, Sexual Violence (Post-Rape Care)	1
	15-19, Female, Physical and/or Emotional Violence	248
	15-19, Female, Sexual Violence (Post-Rape Care)	308
	15-19, Male, Physical and/or Emotional Violence	184
	20-24, Female, Physical and/or Emotional Violence	256
	20-24, Female, Sexual Violence (Post-Rape Care)	115
	20-24, Male, Physical and/or Emotional Violence	61
	50+, Female, Physical and/or	24



	Emotional Violence	
	50+, Female, Sexual Violence (Post-Rape Care)	11
	50+, Male, Physical and/or Emotional Violence	21
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	607
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	389
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	201
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	210
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	185
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	206
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	185
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	189
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	141
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	183



	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	200
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	142
GEND_GBV_TA	Number of people receiving post-GBV care	303
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	202
	By type of service: Sexual Violence (Post-Rape Care)	101
	By PEP service provision (related to sexual violence services provided)	98
	<10, Female, Physical and/or Emotional Violence	1
	<10, Female, Sexual Violence (Post-Rape Care)	6
	<10, Male, Physical and/or Emotional Violence	9
	10-14, Female, Physical and/or Emotional Violence	5
	10-14, Female, Sexual Violence (Post-Rape Care)	13
	10-14, Male, Physical and/or Emotional Violence	11
	15-19, Female, Physical and/or Emotional Violence	15
	15-19, Female, Sexual Violence (Post-Rape Care)	16
	20-24, Female, Physical and/or Emotional Violence	15



	20-24, Female, Sexual Violence (Post-Rape Care)	3
	20-24, Male, Physical and/or Emotional Violence	1
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	88
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	58
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	1
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	21
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	2
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	1
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	12
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	1
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	9
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	12
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	2



	enceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	1
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	68,087
	Age/Sex: 10-14 Male	9,863
	Age/Sex: 15-17 Male	9,892
	By: Age/sex: Male 18-24	1,361
	By: Age/sex: Male 25+	1,372
	Age/Sex: 10-14 Female	12,028
	Age/Sex: 15-17 Female	12,130
	By: Age/sex: 18-24 Female	5,392
	By: Age/sex: 25+ Female	5,493
	Sum of Age/Sex disaggregates	43,913
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	3,088
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	2,796
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	2,389
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	1,838
Required only for DREAMS countries - By service, age and	7,584	



	sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,157
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1,371
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	15,166
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	11,972
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	12,341
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	161
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	1,770
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	10,172
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	10,481
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	161
	Age/Sex: <1	2,642



	Age/Sex: 1-9	7,953
	Program Completion: Active	68,087
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	61 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	41,269
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	68,087
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,005
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented	1,663



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,297
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	17
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB	8



	cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	84 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	87,403
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	103,515
	By Age/Sex (Denominator): <15, Female	2,108
	By Age/Sex (Denominator): <15, Male	2,106
	By Age/Sex (Denominator): 15+, Female	33,504
	By Age/Sex (Denominator): 15+, Male	65,812
	By Age/Sex (Numerator): <15, Female	1,596
	By Age/Sex (Numerator): <15, Male	2,169
	By Age/Sex (Numerator): 15+, Female	27,940



	By Age/Sex (Numerator): 15+, Male	55,722
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	33,557
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	33,705
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	23
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	446
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	28,517
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	28,680
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	22
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	424
TB_PREV_TA	TB_PREV_TA TB_PREV_TA	85 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive	859



	Therapy (IPT) during the reporting period	
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,005
	By Age/Sex (Denominator): <15, Female	18
	By Age/Sex (Denominator): <15, Male	18
	By Age/Sex (Denominator): 15+, Female	323
	By Age/Sex (Denominator): 15+, Male	646
	By Age/Sex (Numerator): <15, Female	15
	By Age/Sex (Numerator): <15, Male	18
	By Age/Sex (Numerator): 15+, Female	280
	By Age/Sex (Numerator): 15+, Male	553
	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	494
	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New,	506



	Positive	
	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	428
	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	431
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were started on TB treatment during the reporting period.	209
	Number of ART patients who were screened for TB at least once during the reporting period	167,484
	Numerator: By Aggregated Age/Sex: <15, Female	11
	Numerator: By Aggregated Age/Sex: <15, Male	11
	Numerator: By Aggregated Age/Sex: 15+, Female	88
	Numerator: By Aggregated Age/Sex: 15+, Male	99
	Denominator: By Aggregated Age/Sex: <15, Female	4,482
	Denominator: By Aggregated Age/Sex: <15, Male	4,032
	Denominator: By Aggregated Age/Sex: 15+, Female	113,095
	Denominator: By Aggregated Age/Sex: 15+, Male	56,442



	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	176,111
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	176,113
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	72,167
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	17,608
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	70,350
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	16,977
TX_TB_TA	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	4,865
	Denominator: By Aggregated Age/Sex: <15, Female	39
	Denominator: By Aggregated Age/Sex: <15, Male	44
	Denominator: By Aggregated Age/Sex: 15+, Female	981
	Denominator: By Aggregated Age/Sex: 15+, Male	913



	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,977
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,977
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	792
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	195
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	795
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	184
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7,353
	By infants who received a virologic test within 2 months of birth	5,879
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,474
	Sum of Infant Age disaggregates	7,353
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants	n/a



	born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	330
	By infants who received a virologic test within 2 months of birth	270
	By infants who received their first virologic HIV test between 2 and 12 months of age	60
	Sum of Infant Age disaggregates	330
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	180,735
	Age/Sex: 15-19 Male	2,198
	Age/Sex: 15-19 Female	3,916
	Age/Sex: <1	312
	Age/Sex: <1-9	5,267
	Age/Sex: 10-14 Male	3,018
	Age/Sex: 10-14 Female	2,443
	Age/Sex: 20-24 Male	2,394
	Age/Sex: 50+ Male	14,057
	Age/Sex: 20-24 Female	9,830
	Age/Sex: 50+ Female	15,242
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	17,141
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	6,839
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	20,017
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	10,852
TX_CURR_N_DSD_Age_Sex_HIV	17,331	



	Status 35-39, Female, Positive	
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	13,419
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	22,610
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	18,123
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,638
	Age/Sex: 15-19 Male	30
	Age/Sex: 15-19 Female	61
	Sum of Age/Sex disaggregations	91
	Age/Sex: <1	5
	Age/Sex: 1-9	109
	Age/Sex: 10-14 Male	51
	Age/Sex: 10-14 Female	55
	Age/Sex: 20-24 Male	29
	Age/Sex: 50+ Male	215
	Age/Sex: 20-24 Female	161
	Age/Sex: 50+ Female	397
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive	326
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive	147
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive	238
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive	144
TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive	304	
TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive	229	



	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	509
	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	281
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	15,530
	By Age/Sex: <1	88
	By Age/Sex: 1-9	906
	By Age/Sex: 10-14 Male	434
	By Age/Sex: 15-19 Male	255
	By Age/Sex: 20-24 Male	405
	By Age/Sex: 50+ Male	689
	By Age/Sex: 10-14 Female	436
	By Age/Sex: 15-19 Female	376
	By Age/Sex: 20-24 Female	951
	By Age/Sex: 50+ Female	231
	Pregnancy status	2,856
	Breastfeeding status	466
	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,037
	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,331
	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	817
	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,609
	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,078
TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,735	
TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	901	



	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	1,697
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	937
	By Age/Sex: <1	5
	By Age/Sex: 1-9	30
	By Age/Sex: 10-14 Male	15
	By Age/Sex: 15-19 Male	18
	By Age/Sex: 20-24 Male	24
	By Age/Sex: 50+ Male	43
	By Age/Sex: 10-14 Female	16
	By Age/Sex: 15-19 Female	25
	By Age/Sex: 20-24 Female	88
	By Age/Sex: 50+ Female	15
	Sum of Age/Sex disaggregates	244
	Pregnancy status	191
	Breastfeeding status	5
	People in prisons and other enclosed settings	37
	TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Female, Positive	67
	TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Male, Positive	84
	TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Female, Positive	47
	TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Male, Positive	103
	TX_NEW_N_TA_Age_Sex_HIVSta tus 35-39, Female, Positive	66
TX_NEW_N_TA_Age_Sex_HIVSta tus 35-39, Male, Positive	105	
TX_NEW_N_TA_Age_Sex_HIVSta	56	



	tus 40-49, Female, Positive	
	TX_NEW_N_TA_Age_Sex_HIVSta tus 40-49, Male, Positive	104
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	171,945
	Denominator: Indication: Routine	2,577
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	5,243
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	65,764
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	5,258
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	96,374
	TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)
Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records		4,452



	in the past 12 months.	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	153
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	161
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,784
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,943
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	95 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	28,572
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	30,220
	Numerator by Status: Pregnant	5,887
	Numerator by Status: Breastfeeding	1,180
	Denominator by Status: Pregnant	10,390
	Denominator by Status: Breastfeeding	5,061
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,286
	Aggregated Age/Sex: 15+ Male	6,356



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,407
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,144
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,268
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,245
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	1,298



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18,394
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	95 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,075
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,279
	Numerator by Status: Pregnant	59
	Numerator by Status: Breastfeeding	7
	Denominator by Status: Pregnant	2,138
	Denominator by Status: Breastfeeding	2,172
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	727



	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	786
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	764
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,751
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	166
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,165
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	201



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,746



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10703	Management Sciences for Health	NGO	U.S. Agency for International Development		
11673	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense		
14201	Mothers 2 Mothers	NGO	U.S. Agency for International Development		
17389	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	75,000
17454	Centre for HIV and AIDS Prevention Studies Eswatini	NGO	U.S. Agency for International Development	GHP-State	3,471,549
17455	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	40,571
17458	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,880,000
17460	University Research	Private Contractor	U.S. Department of Health and	GHP-State	5,478,361



	Corporation, LLC		Human Services/Centers for Disease Control and Prevention		
17461	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,378,048
17462	Ministry of Health and Social Welfare, Eswatini	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,713,711
17463	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,459,152
17464	Pact	Multi-lateral Agency	U.S. Agency for International Development		
17465	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	4,577,351
17965	Catholic Relief Services	FBO	U.S. Agency for International Development		
17966	Population	NGO	U.S. Agency for	GHP-State	940,000



	Services International		International Development		
17967	The Luke Commission	FBO	U.S. Agency for International Development	GHP-State	742,500
17972	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development		
18169	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,638,471
18250	WHO/AFRO	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	450,000
18272	TBD	TBD	Redacted	Redacted	Redacted
18329	Institute for Health Measurement	NGO	U.S. Agency for International Development	GHP-State	2,213,504
18331	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-USAID	1,858,512
18387	FHI 360	NGO	U.S. Agency for International Development	GHP-State	1,530,187
18598	Population Council	NGO	U.S. Agency for International Development	GHP-State	400,000
18599	mother2mothers organisation	NGO	U.S. Agency for International	GHP-State	1,247,742



			Development		
18600	Pact, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	9,886,365
18601	Johns Hopkins University Center for Communication Programs	University	U.S. Agency for International Development	GHP-State	2,350,391
18602	TBD	TBD	Redacted	Redacted	Redacted
70329	TBD	TBD	Redacted	Redacted	Redacted
70330	Baylor College of Medicine Children's Foundation Malawi	NGO	U.S. Agency for International Development	GHP-State	1,685,620
70331	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 10703	Mechanism Name: Systems for Improved Access to Pharmaceuticals and Services Program (SIAPS)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Management Sciences for Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10703	
Mechanism Name:	Systems for Improved Access to Pharmaceuticals and Services Program (SIAPS)	
Prime Partner Name:	Management Sciences for Health	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11673	Mechanism Name: DoD/USDF Umbutfo Eswatini Defence Force
Funding Agency: DOD	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
-----------------------	-----------------------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11673		
Mechanism Name: DoD/USDF Umbutfo Eswatini Defence Force		
Prime Partner Name: U.S. Department of Defense (Defense)		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	0
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
PMTCT_ART_DSD	New on ART	0
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	900
VMMC_CIRC_DSD	By Age: 10-14	20
VMMC_CIRC_DSD	By Age: 15-19	168
VMMC_CIRC_DSD	By Age: 20-24	255
VMMC_CIRC_DSD	By Age: 25-29	223
VMMC_CIRC_DSD	By Age: 50+	5
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	448
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	671
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	900
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	130
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	67
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	32
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	300
PrEP_NEW_DSD	Male 15-19	5



PrEP_NEW_DSD	Male 20-24	10
PrEP_NEW_DSD	Male 50+	5
PrEP_NEW_DSD	Female 15-19	0
PrEP_NEW_DSD	Female 20-24	10
PrEP_NEW_DSD	Female 50+	15
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	20
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	35
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	30
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	40
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	40
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	40
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	35
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	15
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	9,537
PP_PREV_DSD	Age/sex: 10-14 Male	300
PP_PREV_DSD	Age/sex: 15-19 Male	500
PP_PREV_DSD	Age/sex: 20-24 Male	700
PP_PREV_DSD	Age/sex: 50+ Male	400
PP_PREV_DSD	Age/sex: 10-14 Female	300
PP_PREV_DSD	Age/sex: 15-19 Female	550
PP_PREV_DSD	Age/sex: 20-24 Female	850
PP_PREV_DSD	Age/sex: 50+ Female	400
PP_PREV_DSD	Sum of Age/Sex disaggregates	4,000
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	850
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	800
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	937
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	750
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	600
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	600
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	400



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	600
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,578
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	160
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	240
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	4



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	110
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	24



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	4



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	140
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	340



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	250
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	270
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	240
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	145
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	120
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	205
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	57
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	15



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	367
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	387
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	30
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	140
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	37
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	160
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	35
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	148
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	40
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	164
GEND_GBV_DSD	Number of people receiving post-GBV care	55
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	44



GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	11
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	3
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	5
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	5
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	6
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	6
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	5
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	3

	40-49, Female, Physical and/or Emotional Violence	
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	2
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	271
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	120
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	126
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_DSD	Sum of Infant Age disaggregates	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,173
TX_CURR_DSD	Age/Sex: 15-19 Male	61
TX_CURR_DSD	Age/Sex: 15-19 Female	40
TX_CURR_DSD	Sum of age/sex disaggregates	101
TX_CURR_DSD	Age/Sex: <1	10
TX_CURR_DSD	Age/Sex: <1-9	40



TX_CURR_DSD	Age/Sex: 10-14 Male	22
TX_CURR_DSD	Age/Sex: 10-14 Female	19
TX_CURR_DSD	Age/Sex: 20-24 Male	86
TX_CURR_DSD	Age/Sex: 50+ Male	346
TX_CURR_DSD	Age/Sex: 20-24 Female	251
TX_CURR_DSD	Age/Sex: 50+ Female	128
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	309
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	294
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	518
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	412
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	298
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	468
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	376
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	495
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	571
TX_NEW_DSD	By Age/Sex: 10-14 Male	1
TX_NEW_DSD	By Age/Sex: 15-19 Male	5
TX_NEW_DSD	By Age/Sex: 20-24 Male	32
TX_NEW_DSD	By Age/Sex: 50+ Male	16
TX_NEW_DSD	By Age/Sex: 10-14 Female	0
TX_NEW_DSD	By Age/Sex: 15-19 Female	5
TX_NEW_DSD	By Age/Sex: 20-24 Female	21
TX_NEW_DSD	By Age/Sex: 50+ Female	10
TX_NEW_DSD	Sum of Age/Sex disaggregates	90



TX_NEW_DSD	Pregnancy status	2
TX_NEW_DSD	Breastfeeding status	5
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	43
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	57
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	67
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	84
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	59
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	99
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	28
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	44
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,577
TX_PVLS_DSD	Denominator: Indication: Routine	2,577
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	120
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,120
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	137
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,200
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,059
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	1,241



	period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Breastfeeding	5
TX_RET_DSD	Denominator by Status: Breastfeeding	7
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	47
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	460
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	55
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	497
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	60
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	540
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	577



	stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	1,620
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	40
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	200
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	250
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	200
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	220
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	10



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	60
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	120
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	40
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	50
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	100
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,520
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	464
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	488
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	24
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	24
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	210
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	230
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	22



TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	24
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	195
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	223
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	19
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	23
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	446
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	18
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	22
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	424
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	209
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	2,087
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	11
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	11
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	88
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	99
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	101
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	104
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	895
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	987



TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	198
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	198
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	1,784
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	21
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	94
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	188

Implementing Mechanism Details

Mechanism ID: 14201	Mechanism Name: Reducing Infection through Support & Eduation (RISE)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Mothers 2 Mothers	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 14201 Mechanism Name: Reducing Infection through Support & Education (RISE) Prime Partner Name: Mothers 2 Mothers		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17389	Mechanism Name: Vast Grants
Funding Agency: PC	Procurement Type: Grant
Prime Partner Name: U.S. Peace Corps	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 75,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 75,000	
Funding Source	Funding Amount
GHP-State	75,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17389		
Mechanism Name: Vast Grants		
Prime Partner Name: U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	7,500
Strategic Area	Budget Code	Planned Amount
Care	HKID	45,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	22,500
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,530
PP_PREV_DSD	Age/sex: 10-14 Male	154
PP_PREV_DSD	Age/sex: 15-19 Male	876
PP_PREV_DSD	Age/sex: 20-24 Male	584
PP_PREV_DSD	Age/sex: 50+ Male	69
PP_PREV_DSD	Age/sex: 10-14 Female	146
PP_PREV_DSD	Age/sex: 15-19 Female	1,026
PP_PREV_DSD	Age/sex: 20-24 Female	876
PP_PREV_DSD	Age/sex: 50+ Female	69
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,800
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	73
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	73
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	73
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	73
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	146
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	69
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	138
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	69
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR	2,061



	OVC programs for children and families affected by HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 10-14 Male	354
OVC_SERV_DSD	Age/Sex: 15-17 Male	383
OVC_SERV_DSD	By: Age/sex: Male 18-24	39
OVC_SERV_DSD	By: Age/sex: Male 25+	50
OVC_SERV_DSD	Age/Sex: 10-14 Female	408
OVC_SERV_DSD	Age/Sex: 15-17 Female	510
OVC_SERV_DSD	By: Age/sex: 18-24 Female	111
OVC_SERV_DSD	By: Age/sex: 25+ Female	212
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,655
OVC_SERV_DSD	Age/Sex: 1-9	29
OVC_SERV_DSD	Program Completion: Active	2,061

Implementing Mechanism Details

Mechanism ID: 17454	Mechanism Name: CHAPS VMMC
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Centre for HIV and AIDS Prevention Studies Eswatini	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,471,549	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,471,549	
Funding Source	Funding Amount
GHP-State	3,471,549

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	22,000
Focus Area:	Changing harmful gender norms and promoting



	positive gender norms
Sub Area:	Implementation

Budget Code Information

Mechanism ID: 17454		
Mechanism Name: CHAPS VMMC		
Prime Partner Name: Centre for HIV and AIDS Prevention Studies Eswatini		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	3,471,549



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	22,980
VMMC_CIRC_DSD	By Age: 10-14	5,521
VMMC_CIRC_DSD	By Age: 15-19	9,093
VMMC_CIRC_DSD	By Age: 20-24	3,443
VMMC_CIRC_DSD	By Age: 25-29	1,245
VMMC_CIRC_DSD	By Age: 50+	92
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	18,149
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	19,394
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	22,980
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	2,209
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	921
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	460
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	23,050
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	10,420
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	303
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	5,955
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	171
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	1,563
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	1,786
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,116



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	893
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	671
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	18

Implementing Mechanism Details

Mechanism ID: 17455	Mechanism Name: PEPFAR Small Grants Program
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 40,571	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 40,571	
Funding Source	Funding Amount
GHP-State	40,571

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17455		
Mechanism Name: PEPFAR Small Grants Program		
Prime Partner Name: U.S. Department of State		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	40,571
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17458	Mechanism Name: ICAP – Epi-Research TA
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,880,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,880,000	
Funding Source	Funding Amount
GHP-State	1,880,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	56,400
----------------------------	--------

Budget Code Information

Mechanism ID:	17458	
Mechanism Name:	ICAP – Epi-Research TA	
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	366,240
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	1,007,708
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	506,052
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17460	Mechanism Name: URC - Lubombo
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,478,361	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,478,361	
Funding Source	Funding Amount
GHP-State	5,478,361

Cross-Cutting Budget Attribution(s)

Gender: GBV	116,323
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Key Populations: FSW	12,795
Focus Area:	Implementation of core HIV prevention interventions



	for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	4,265
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs
Condom programming	10,000
Water	45,000
Human Resources for Health	119,105

Budget Code Information

Mechanism ID: 17460		
Mechanism Name: URC - Lubombo		
Prime Partner Name: University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,284,977
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	884,832
Strategic Area	Budget Code	Planned Amount



Care	PDCS	543,665
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	58,806
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	276,651
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	445,189
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	102,323



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,737,469
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	144,449

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,489
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,102
PMTCT_ART_DSD	New on ART	484
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,005
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	14
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	122
PMTCT_ART_TA	New on ART	4
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	10
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,102
PMTCT_STAT_DSD	Number of new ANC and L&D clients	5,602



PMTCT_STAT_DSD	By Age (Denominator): 10-14	53
PMTCT_STAT_DSD	By Age (Denominator): <15-19	814
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,549
PMTCT_STAT_DSD	By Number of known positives: 10-14	12
PMTCT_STAT_DSD	By Number of known positives: 15-19	184
PMTCT_STAT_DSD	By Number of known positives: 20-24	340
PMTCT_STAT_DSD	By Number of new positives: 10-14	4
PMTCT_STAT_DSD	By Number of new positives: 15-19	50
PMTCT_STAT_DSD	By Number of new positives: 20-24	73
PMTCT_STAT_DSD	By Number of new negative: 10-14	35
PMTCT_STAT_DSD	By Number of new negative: 15-19	532
PMTCT_STAT_DSD	By Number of new negative: 20-24	711
PMTCT_STAT_DSD	By Age (Numerator): 10-14	60
PMTCT_STAT_DSD	By Age (Numerator): 15-19	768
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,133
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	1,788
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	808
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	535
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	55
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	336
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	1,056
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	112
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	177
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	712
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	74
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	118



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	425
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	45
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	9
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	72
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	3
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	1,511
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	960
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	581
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	89
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	122
PMTCT_STAT_TA	Number of new ANC and L&D clients	126
PMTCT_STAT_TA	By Age (Denominator): 10-14	2
PMTCT_STAT_TA	By Age (Denominator): 15-19	8
PMTCT_STAT_TA	By Age (Denominator): 20-24	37
PMTCT_STAT_TA	By known positives: 20-24	7
PMTCT_STAT_TA	By new positives: 20-24	2
PMTCT_STAT_TA	By new negatives: 20-24	18
PMTCT_STAT_TA	By Age (Numerator): : 15-19	2
PMTCT_STAT_TA	By Age (Numerator): 20-24	27
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	42
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	22
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	14
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	1
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	9
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult	31



	25-29, Female, Newly Identified Negative	
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	3
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	5
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	31
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	3
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	3
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	5
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	44
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	38
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	9
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	2
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,040
VMMC_CIRC_DSD	By Age: 10-14	244
VMMC_CIRC_DSD	By Age: 15-19	418
VMMC_CIRC_DSD	By Age: 20-24	158
VMMC_CIRC_DSD	By Age: 25-29	58
VMMC_CIRC_DSD	By Age: 50+	4
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	824
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	882
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	1,040
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	98
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	42
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	20



PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	464
PrEP_NEW_DSD	Male 15-19	28
PrEP_NEW_DSD	Male 20-24	32
PrEP_NEW_DSD	Female 15-19	46
PrEP_NEW_DSD	Female 20-24	51
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	51
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	32
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	46
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	28
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	51
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	28
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	46
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	23
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,855
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	77
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	192
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	249
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	148
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	546



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	348
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	296
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	6,739
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	137
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	1



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	472
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	270
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	70
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	74
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	81
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	151
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	112
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male,	90



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	163
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	593
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	730
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	1



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	133
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	164
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	172
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	152
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	72
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	168
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	8



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	447



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	545
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	298
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	545
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	245
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	495
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	245
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	545
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	729
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	74



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	729
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	557
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	58
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	136
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	14



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	80
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	2



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	30
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,118
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	16
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	35
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	19
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	418
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	26
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	32
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1



HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	13
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	14
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	9
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	15
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	6
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	11
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	6
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	1



	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	28
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	35
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	18
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	35
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	15
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	31
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	15
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	35
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	33
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	33
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	3



	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	25
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	3
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	3
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	3
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	4
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14,	12



	Female, Unassisted	
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	4
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	5
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	4
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	5
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male,	15



	Directly-Assisted	
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	59
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Other	124
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	124
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	129
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	604
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	606
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	324



TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	237
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	18
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	322
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	18
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	238
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	30
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	30
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	10
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of	1



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
GEND_GBV_DSD	Number of people receiving post-GBV care	883
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	585
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	298
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	297
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	6
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	18
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	30
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	42
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	43
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	54
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	36
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	38
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	9
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	23
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	19
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	49
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	48

	25-29, Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	58
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	49
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	48
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	51
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	44
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	46
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	28
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	44
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	45
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	28
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	509
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	283
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	2

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	222
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	15
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,451
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,163
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	288
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,451
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	59
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	47
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	12
PMTCT_EID_TA	Sum of Infant Age disaggregates	59
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	42,723
TX_CURR_DSD	Age/Sex: 15-19 Male	369



TX_CURR_DSD	Age/Sex: 15-19 Female	752
TX_CURR_DSD	Sum of age/sex disaggregates	1,121
TX_CURR_DSD	Age/Sex: <1	82
TX_CURR_DSD	Age/Sex: <1-9	1,533
TX_CURR_DSD	Age/Sex: 10-14 Male	635
TX_CURR_DSD	Age/Sex: 10-14 Female	641
TX_CURR_DSD	Age/Sex: 20-24 Male	485
TX_CURR_DSD	Age/Sex: 50+ Male	3,053
TX_CURR_DSD	Age/Sex: 20-24 Female	2,234
TX_CURR_DSD	Age/Sex: 50+ Female	4,175
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,982
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,840
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4,175
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,473
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,102
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,937
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	6,336
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	3,926
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,700
TX_CURR_TA	Age/Sex: 15-19 Male	14
TX_CURR_TA	Age/Sex: 15-19 Female	35
TX_CURR_TA	Sum of Age/Sex disaggregations	49
TX_CURR_TA	Age/Sex: <1	4
TX_CURR_TA	Age/Sex: 1-9	72



TX_CURR_TA	Age/Sex: 10-14 Male	22
TX_CURR_TA	Age/Sex: 10-14 Female	25
TX_CURR_TA	Age/Sex: 20-24 Male	13
TX_CURR_TA	Age/Sex: 50+ Male	117
TX_CURR_TA	Age/Sex: 20-24 Female	90
TX_CURR_TA	Age/Sex: 50+ Female	201
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	131
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	69
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	131
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	69
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	178
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	110
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	279
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	137
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,117
TX_NEW_DSD	By Age/Sex: <1	10
TX_NEW_DSD	By Age/Sex: 1-9	160
TX_NEW_DSD	By Age/Sex: 10-14 Male	86
TX_NEW_DSD	By Age/Sex: 15-19 Male	37
TX_NEW_DSD	By Age/Sex: 20-24 Male	54
TX_NEW_DSD	By Age/Sex: 50+ Male	109
TX_NEW_DSD	By Age/Sex: 10-14 Female	87
TX_NEW_DSD	By Age/Sex: 15-19 Female	54
TX_NEW_DSD	By Age/Sex: 20-24 Female	125



TX_NEW_DSD	By Age/Sex: 50+ Female	34
TX_NEW_DSD	Sum of Age/Sex disaggregates	586
TX_NEW_DSD	Pregnancy status	225
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	141
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	179
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	108
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	212
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	141
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	221
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	127
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	232
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	106
TX_NEW_TA	By Age/Sex: <1	1
TX_NEW_TA	By Age/Sex: 1-9	6
TX_NEW_TA	By Age/Sex: 10-14 Male	4
TX_NEW_TA	By Age/Sex: 15-19 Male	1
TX_NEW_TA	By Age/Sex: 20-24 Male	3
TX_NEW_TA	By Age/Sex: 50+ Male	5
TX_NEW_TA	By Age/Sex: 10-14 Female	1
TX_NEW_TA	By Age/Sex: 15-19 Female	2
TX_NEW_TA	By Age/Sex: 20-24 Female	7
TX_NEW_TA	By Age/Sex: 50+ Female	1
TX_NEW_TA	Sum of Age/Sex disaggregates	24
TX_NEW_TA	Pregnancy status	10



TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	8
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	10
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	6
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	15
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	8
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	11
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	7
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	10
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	42,328
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,281
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	16,358
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,281
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	24,102
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,700
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	68
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	78



TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,269
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	860
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,453
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,996
TX_RET_DSD	Numerator by Status: Pregnant	3,448
TX_RET_DSD	Numerator by Status: Breastfeeding	342
TX_RET_DSD	Denominator by Status: Pregnant	3,252
TX_RET_DSD	Denominator by Status: Breastfeeding	756
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	417
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,558
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	309
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,169
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	438
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	3,798



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	333
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,426
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	41
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	55
TX_RET_TA	Numerator by Status: Pregnant	10
TX_RET_TA	Numerator by Status: Breastfeeding	1
TX_RET_TA	Denominator by Status: Pregnant	13
TX_RET_TA	Denominator by Status: Breastfeeding	1
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the	1



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	213
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	111
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	109
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	111
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	324
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	536
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24,	324



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	536
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	324
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	536
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	324
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	536
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	324
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	536
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	324
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	536
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	324
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	536
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	324
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	536
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	324
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	536
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	324
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	536



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	324
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	1,069
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	2,254
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	2,254
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	2,322
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	17,333
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	20,393
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	405
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	402
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	6,564
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	13,034
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	305
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	419
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	5,587
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	10,973
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	10,177
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV	10,297



	Alternative TPT Regimen, Life-long ART, New, Positive	
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	8,651
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	8,771
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	537
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	630
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	13
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	13
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	202
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	404
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	10
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	12
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	172
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	343
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	315
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	315
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	268
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV	268



	Alternative TPT Regimen, Life-long ART, New, Positive	
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	32,523
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,072
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	963
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	27,466
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	13,588
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	43,089
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	43,089
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	17,234
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	4,308
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	17,234
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	4,308
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	4,218
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	26
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	26
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	640
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	639
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,333
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,333
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	533
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV	134



	Life-long ART, Already, TB Screen - Positive, Positive	
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	533
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	134

Implementing Mechanism Details

Mechanism ID: 17461	Mechanism Name: ICAP Lab
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,378,048	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,378,048	
Funding Source	Funding Amount
GHP-State	2,378,048

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17461	
Mechanism Name:	ICAP Lab	
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	1,805,826
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	279,127
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	39,488
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	253,607
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17462	Mechanism Name: Strengthening MOH Leadership, Governance & Quality Management
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Welfare, Eswatini	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 1,713,711	Total Mechanism Pipeline: N/A



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,713,711	
Funding Source	Funding Amount
GHP-State	1,713,711

Cross-Cutting Budget Attribution(s)

Human Resources for Health	606,531
----------------------------	---------

Budget Code Information

Mechanism ID:	17462	
Mechanism Name:	Strengthening MOH Leadership, Governance & Quality	
Prime Partner Name:	Management Ministry of Health and Social Welfare, Eswatini	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,462,382
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	251,329
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17463	Mechanism Name: ICAP-Manzini
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,459,152	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,459,152	
Funding Source	Funding Amount
GHP-State	5,459,152

Cross-Cutting Budget Attribution(s)

Water	45,000
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Gender: GBV	93,736
Focus Area:	GBV Prevention
Sub Area:	Implementation
Key Populations: FSW	10,913
Focus Area:	Implementation of core HIV prevention interventions



	for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	3,638
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Human Resources for Health	121,692
Condom programming	10,000

Budget Code Information

Mechanism ID:	17463	
Mechanism Name:	ICAP-Manzini	
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,476,120
Strategic Area	Budget Code	Planned Amount
Care	HVTB	451,459
Strategic Area	Budget Code	Planned Amount
Care	PDCS	286,682
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	44,957
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	281,151



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	835,287
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	195,376
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,767,091
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	121,029

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,635
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,156
PMTCT_ART_DSD	New on ART	1,189
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,446
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	55
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	135
PMTCT_ART_TA	New on ART	25
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	30
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	8,156



	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	8,591
PMTCT_STAT_DSD	By Age (Denominator): 10-14	85
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,290
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,492
PMTCT_STAT_DSD	By Number of known positives: 10-14	19
PMTCT_STAT_DSD	By Number of known positives: 15-19	294
PMTCT_STAT_DSD	By Number of known positives: 20-24	551
PMTCT_STAT_DSD	By Number of new positives: 10-14	8
PMTCT_STAT_DSD	By Number of new positives: 15-19	130
PMTCT_STAT_DSD	By Number of new positives: 20-24	169
PMTCT_STAT_DSD	By Number of new negative: 10-14	53
PMTCT_STAT_DSD	By Number of new negative: 15-19	796
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,084
PMTCT_STAT_DSD	By Age (Numerator): 10-14	82
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,205
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,811
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	2,491
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	1,288
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	859
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	86
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	553
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	1,615
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	259
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	287
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	1,098
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	176



	30-34, Female, Newly Identified Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	191
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	637
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	106
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	17
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	105
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	15
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	2,431
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,555
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	926
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	146
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	135
PMTCT_STAT_TA	Number of new ANC and L&D clients	142
PMTCT_STAT_TA	By Age (Denominator): 15-19	21
PMTCT_STAT_TA	By Age (Denominator): 20-24	42
PMTCT_STAT_TA	By known positives: 20-24	12
PMTCT_STAT_TA	By new positives: 15-19	1
PMTCT_STAT_TA	By new positives: 20-24	4
PMTCT_STAT_TA	By new negatives: 15-19	5
PMTCT_STAT_TA	By new negatives: 20-24	20
PMTCT_STAT_TA	By Age (Numerator): : 15-19	12
PMTCT_STAT_TA	By Age (Numerator): 20-24	34
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	40
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	22
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	15



PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	12
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	23
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	5
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	6
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	23
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	5
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	4
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	4
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	1
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	1
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	41
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	36
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	10
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	2
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	2,773
VMMC_CIRC_DSD	By Age: 10-14	664
VMMC_CIRC_DSD	By Age: 15-19	1,101
VMMC_CIRC_DSD	By Age: 20-24	417
VMMC_CIRC_DSD	By Age: 25-29	151
VMMC_CIRC_DSD	By Age: 50+	12



VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	2,194
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	2,345
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	2,773
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	265
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	112
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	56
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	774
PrEP_NEW_DSD	Male 15-19	46
PrEP_NEW_DSD	Male 20-24	54
PrEP_NEW_DSD	Female 15-19	78
PrEP_NEW_DSD	Female 20-24	84
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	84
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	54
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	78
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	46
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	84
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	46
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	78
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	39
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	33,883
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male,	18



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	61
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	750
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	454
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	31



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,649
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	117
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,049
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	899
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,216
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	1,257
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	719
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	188
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	114
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	33



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	67
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	244
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	156
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	135
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	61
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	922
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	152
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,144
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	177
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	7



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	196
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	124
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	198
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	248
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	136
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	248
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	111
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	32



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	223
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	111
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	248
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	54
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	61



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,354
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	98
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,651
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	898
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,651
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	748
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,502
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	107



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	748
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,651
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	1,143
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	178
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,143
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	178
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	868
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	133
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	217
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	12



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	92
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	156
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	15



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	85
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	174
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	85
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	190
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	216
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	135
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	80



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	524
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	39
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	26
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	53
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29,	2



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	34
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	41
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	22
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	41
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	18
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	37
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	18
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	41
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	6
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	6
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	4

	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	3
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	3
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	3
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	3
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	3
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,681
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,682
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	48
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	883
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	51



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	699
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	48
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	882
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	51
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	701
GEND_GBV_DSD	Number of people receiving post-GBV care	1,786
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	935
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	432
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	419
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	53
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	93
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	60
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	102
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	160
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	107
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	116
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	59
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	36
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	51

GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	94
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	113
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	69
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	86
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	113
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	67
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	86
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	89
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	67
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	86
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	89
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,202
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	658
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The	5



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	534
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,638
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,114
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	524
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,638
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	49
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	43
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	6
PMTCT_EID_TA	Sum of Infant Age disaggregates	49
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	55,373
TX_CURR_DSD	Age/Sex: 15-19 Male	889
TX_CURR_DSD	Age/Sex: 15-19 Female	984
TX_CURR_DSD	Sum of age/sex disaggregates	1,873
TX_CURR_DSD	Age/Sex: <1	54
TX_CURR_DSD	Age/Sex: <1-9	1,167
TX_CURR_DSD	Age/Sex: 10-14 Male	903
TX_CURR_DSD	Age/Sex: 10-14 Female	357
TX_CURR_DSD	Age/Sex: 20-24 Male	746
TX_CURR_DSD	Age/Sex: 50+ Male	3,901
TX_CURR_DSD	Age/Sex: 20-24 Female	3,301



TX_CURR_DSD	Age/Sex: 50+ Female	3,978
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	5,505
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,247
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	7,057
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,979
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	5,398
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,835
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	6,279
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	5,793
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,015
TX_CURR_TA	Age/Sex: 15-19 Male	19
TX_CURR_TA	Age/Sex: 15-19 Female	42
TX_CURR_TA	Sum of Age/Sex disaggregations	61
TX_CURR_TA	Age/Sex: 1-9	58
TX_CURR_TA	Age/Sex: 10-14 Male	28
TX_CURR_TA	Age/Sex: 10-14 Female	30
TX_CURR_TA	Age/Sex: 20-24 Male	19
TX_CURR_TA	Age/Sex: 50+ Male	149
TX_CURR_TA	Age/Sex: 20-24 Female	107
TX_CURR_TA	Age/Sex: 50+ Female	254
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	178
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	96



TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	178
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	96
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	39
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	152
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	380
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	190
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,874
TX_NEW_DSD	By Age/Sex: <1	5
TX_NEW_DSD	By Age/Sex: 1-9	76
TX_NEW_DSD	By Age/Sex: 10-14 Male	39
TX_NEW_DSD	By Age/Sex: 15-19 Male	95
TX_NEW_DSD	By Age/Sex: 20-24 Male	139
TX_NEW_DSD	By Age/Sex: 50+ Male	300
TX_NEW_DSD	By Age/Sex: 10-14 Female	30
TX_NEW_DSD	By Age/Sex: 15-19 Female	143
TX_NEW_DSD	By Age/Sex: 20-24 Female	318
TX_NEW_DSD	By Age/Sex: 50+ Female	99
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,163
TX_NEW_DSD	Pregnancy status	1,090
TX_NEW_DSD	Breastfeeding status	61
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	361
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	478
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	273



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	577
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	383
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	619
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	317
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	622
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	646
TX_NEW_TA	By Age/Sex: <1	1
TX_NEW_TA	By Age/Sex: 1-9	6
TX_NEW_TA	By Age/Sex: 10-14 Male	3
TX_NEW_TA	By Age/Sex: 15-19 Male	17
TX_NEW_TA	By Age/Sex: 20-24 Male	18
TX_NEW_TA	By Age/Sex: 50+ Male	38
TX_NEW_TA	By Age/Sex: 10-14 Female	8
TX_NEW_TA	By Age/Sex: 15-19 Female	22
TX_NEW_TA	By Age/Sex: 20-24 Female	49
TX_NEW_TA	By Age/Sex: 50+ Female	14
TX_NEW_TA	Sum of Age/Sex disaggregates	169
TX_NEW_TA	Pregnancy status	124
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	48
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	61
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	37
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	74
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female,	50



	Positive	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	79
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	42
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	79
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	55,202
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,655
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	20,980
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,657
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	30,910
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	581
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	17
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	18
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	325
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	221
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,733
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	6,058



	stopped ART, and those lost to follow-up	
TX_RET_DSD	Denominator by Status: Pregnant	3,074
TX_RET_DSD	Denominator by Status: Breastfeeding	2,610
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,293
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	855
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,461
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,124
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	233
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,673
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	282
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,870



TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,585
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,752
TX_RET_TA	Denominator by Status: Pregnant	2,021
TX_RET_TA	Denominator by Status: Breastfeeding	2,100
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	699
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	659
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	731
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,496
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	137
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,009
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	168



TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,438
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	225
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	450
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	225
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	225
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	225
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	225
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	675
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	1,125
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	675
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1,125
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	675
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1,125
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	675
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,125
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	675



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	1,125
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	675
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	1,125
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	675
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	1,125
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	675
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	1,125
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	675
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	1,125
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	675
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	1,125
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	675
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	2,250
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	4,752
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	4,752
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	4,896
TB_PREV_DSD	The number of ART patients who completed a course	30,477



	of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	35,858
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	741
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	742
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	11,749
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	22,626
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	563
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	759
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	9,384
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	19,182
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	58,766
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,455
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,313
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	37,465
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	18,533
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	58,766
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	58,766
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	23,508
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	5,881
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV	23,508



	Life-long ART, New, TB Screen - Negative, Positive	
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	5,881

Implementing Mechanism Details

Mechanism ID: 17464	Mechanism Name: Rapid and Effective Action for Combating HIV/AIDS III (REACH 3)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17464	
Mechanism Name:	Rapid and Effective Action for Combating HIV/AIDS III (REACH 3)	
Prime Partner Name:	Pact	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17465	Mechanism Name: AIDSFree
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,577,351	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,577,351	
Funding Source	Funding Amount



GHP-State	4,577,351
-----------	-----------

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	11,465
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	3,822
Gender: GBV	120,020
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Food and Nutrition: Commodities	6,000
Water	33,750
Human Resources for Health	103,994
Food and Nutrition: Policy, Tools, and Service Delivery	2,000
Condom programming	7,500

Budget Code Information

Mechanism ID: 17465 Mechanism Name: AIDSFree Prime Partner Name: John Snow, Inc.		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,216,950
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	425,934
Strategic Area	Budget Code	Planned Amount
Care	PDCS	160,812
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,047,444
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	231,098
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,277,799
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	217,314

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,436
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,698
PMTCT_ART_DSD	New on ART	1,304
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,132
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	166
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	516
PMTCT_ART_TA	New on ART	85
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	81
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	7,698



	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	8,090
PMTCT_STAT_DSD	By Age (Denominator): 10-14	82
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,211
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,332
PMTCT_STAT_DSD	By Number of known positives: 10-14	9
PMTCT_STAT_DSD	By Number of known positives: 15-19	286
PMTCT_STAT_DSD	By Number of known positives: 20-24	548
PMTCT_STAT_DSD	By Number of new positives: 15-19	104
PMTCT_STAT_DSD	By Number of new positives: 20-24	132
PMTCT_STAT_DSD	By Number of new negative: 10-14	71
PMTCT_STAT_DSD	By Number of new negative: 15-19	769
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,029
PMTCT_STAT_DSD	By Age (Numerator): 10-14	78
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,159
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,709
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	2,352
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	1,222
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	811
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	80
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	548
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	1,537
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	202
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	281
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	1,033
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	132



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	188
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	616
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	80
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	10
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	118
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	7
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	2,287
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,446
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	884
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	135
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	516
PMTCT_STAT_TA	Number of new ANC and L&D clients	543
PMTCT_STAT_TA	By Age (Denominator): 10-14	6
PMTCT_STAT_TA	By Age (Denominator): 15-19	82
PMTCT_STAT_TA	By Age (Denominator): 20-24	157
PMTCT_STAT_TA	By known positives: 15-19	18
PMTCT_STAT_TA	By known positives: 20-24	38
PMTCT_STAT_TA	By new positives: 15-19	3
PMTCT_STAT_TA	By new positives: 20-24	13
PMTCT_STAT_TA	By new negatives: 15-19	28
PMTCT_STAT_TA	By new negatives: 20-24	77
PMTCT_STAT_TA	By Age (Numerator): : 15-19	49
PMTCT_STAT_TA	By Age (Numerator): 20-24	128
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	156
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	82



PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	54
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	6
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	37
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	107
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	12
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	17
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	106
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	12
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	11
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	28
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	9
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	156
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	135
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	39
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	9
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	577
PrEP_NEW_DSD	Male 15-19	37
PrEP_NEW_DSD	Male 20-24	38
PrEP_NEW_DSD	Female 15-19	57
PrEP_NEW_DSD	Female 20-24	63
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	64
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	38



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	58
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	37
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	64
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	37
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	58
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	31
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	79,282
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	250
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	251
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	11



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	627
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5,599
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	107
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	5,590
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,096
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	657
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,408
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,534
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	7,671
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	252



HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	22,717
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	479
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	3



HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	235
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	227
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	137
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	82
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	300
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	189
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	162
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	577
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	890
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	120
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,090
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	141



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	95
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	140
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	78
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	301
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	191
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	169
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	237
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	247
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	301



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	319
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	162
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	297
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	137
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	319
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	5



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	46
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,976
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	2,588
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,412



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	2,415
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,319
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	2,354
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,179
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,102
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	1,098
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	149
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,098
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	149
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	831
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	107



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	207
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	86
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	65



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	300
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	166
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	314
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	282
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	141
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	311
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	19



HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,146
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	292
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	308
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	49
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	30
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	108
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	64
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	445
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	649
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female,	7



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	39
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	51
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male,	5



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	10
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	12
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	6
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	12
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	6
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	16
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male,	2



	Positive	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	6
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	12
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	82
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	108
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	58
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	100
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	56
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	98
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	50
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	2



	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	46
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	50
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	50
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	40
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	8
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	11
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	14
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	15
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	8
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	7
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	2
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14,	16



	Female, Unassisted	
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	7
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	44
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	44
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	45
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	45
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	45
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	45
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male,	24



	Directly-Assisted	
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	45
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	45
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	45
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	45
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	24
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	117
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Other	197
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	201
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	197
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,154
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,154
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	24
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	647

TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	24
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	459
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	24
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	649
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	24
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	457
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	15
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	15
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	10
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	10
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
GEND_GBV_DSD	Number of people receiving post-GBV care	1,920



GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,266
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	654
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	621
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	21
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	40
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	59
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	35
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	63
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	57
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	98
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	91
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	40
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	97
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	38
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	16
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	501
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	246
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	30
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	86
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	50
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	41
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	69
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	57



	35-39, Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	23
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	69
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	69
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	23
GEND_GBV_TA	Number of people receiving post-GBV care	303
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	202
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	101
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	98
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	1
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	6
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	9
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	5
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	11
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	15
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	16
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	15
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	88
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	58
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34,	21

	Female, Physical and/or Emotional Violence	
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	12
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	9
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	12
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	1
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	757
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	452
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	298

	TB treatment during the reporting period)	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,446
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,951
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	495
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,446
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	166
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	134
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	32
PMTCT_EID_TA	Sum of Infant Age disaggregates	166
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	75,332
TX_CURR_DSD	Age/Sex: 15-19 Male	778
TX_CURR_DSD	Age/Sex: 15-19 Female	2,029
TX_CURR_DSD	Sum of age/sex disaggregates	2,807
TX_CURR_DSD	Age/Sex: <1	129
TX_CURR_DSD	Age/Sex: <1-9	2,173
TX_CURR_DSD	Age/Sex: 10-14 Male	1,247



TX_CURR_DSD	Age/Sex: 10-14 Female	1,237
TX_CURR_DSD	Age/Sex: 20-24 Male	968
TX_CURR_DSD	Age/Sex: 50+ Male	6,081
TX_CURR_DSD	Age/Sex: 20-24 Female	3,817
TX_CURR_DSD	Age/Sex: 50+ Female	6,116
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	7,443
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,084
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	7,961
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	4,614
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	7,020
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	5,577
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	8,896
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	7,162
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,117
TX_CURR_TA	Age/Sex: 15-19 Male	9
TX_CURR_TA	Age/Sex: 15-19 Female	19
TX_CURR_TA	Sum of Age/Sex disaggregations	28
TX_CURR_TA	Age/Sex: <1	1
TX_CURR_TA	Age/Sex: 1-9	22
TX_CURR_TA	Age/Sex: 10-14 Male	18
TX_CURR_TA	Age/Sex: 10-14 Female	19
TX_CURR_TA	Age/Sex: 20-24 Male	9
TX_CURR_TA	Age/Sex: 50+ Male	79
TX_CURR_TA	Age/Sex: 20-24 Female	49



TX_CURR_TA	Age/Sex: 50+ Female	112
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	130
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	54
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	78
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	51
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	112
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	85
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	166
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	104
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,622
TX_NEW_DSD	By Age/Sex: <1	60
TX_NEW_DSD	By Age/Sex: 1-9	502
TX_NEW_DSD	By Age/Sex: 10-14 Male	251
TX_NEW_DSD	By Age/Sex: 15-19 Male	87
TX_NEW_DSD	By Age/Sex: 20-24 Male	138
TX_NEW_DSD	By Age/Sex: 50+ Male	194
TX_NEW_DSD	By Age/Sex: 10-14 Female	261
TX_NEW_DSD	By Age/Sex: 15-19 Female	131
TX_NEW_DSD	By Age/Sex: 20-24 Female	427
TX_NEW_DSD	By Age/Sex: 50+ Female	62
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,551
TX_NEW_DSD	Pregnancy status	1,306
TX_NEW_DSD	Breastfeeding status	167
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29,	366



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	455
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	273
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	540
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	369
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	588
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	318
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	591
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	144
TX_NEW_TA	By Age/Sex: <1	1
TX_NEW_TA	By Age/Sex: 1-9	12
TX_NEW_TA	By Age/Sex: 10-14 Male	7
TX_NEW_TA	By Age/Sex: 20-24 Male	2
TX_NEW_TA	By Age/Sex: 10-14 Female	6
TX_NEW_TA	By Age/Sex: 15-19 Female	1
TX_NEW_TA	By Age/Sex: 20-24 Female	33
TX_NEW_TA	Sum of Age/Sex disaggregates	49
TX_NEW_TA	Pregnancy status	57
TX_NEW_TA	Breastfeeding status	5
TX_NEW_TA	People in prisons and other enclosed settings	37
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	11
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	13
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female,	4



	Positive	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	13
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	8
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	13
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	7
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	13
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	53,046
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,622
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	20,167
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,618
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	29,639
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,258
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	71
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	69
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,239
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	879
TX_RET_DSD	Number of adults and children who are still alive and on	8,213



	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,644
TX_RET_DSD	Numerator by Status: Pregnant	2,439
TX_RET_DSD	Numerator by Status: Breastfeeding	294
TX_RET_DSD	Denominator by Status: Pregnant	2,569
TX_RET_DSD	Denominator by Status: Breastfeeding	308
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	406
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,216
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	452
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,991
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	419
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,261
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	474

	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,486
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	396
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	416
TX_RET_TA	Numerator by Status: Pregnant	49
TX_RET_TA	Numerator by Status: Breastfeeding	6
TX_RET_TA	Denominator by Status: Pregnant	52
TX_RET_TA	Denominator by Status: Breastfeeding	6
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	112
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	234
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the	116



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	249
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	165
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	332
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	165
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	165
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	165
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	165
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	499
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	828
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	499
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	828
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	499



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	828
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	499
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	828
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	499
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	828
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	499
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	828
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	499
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	829
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	499
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	829
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	499
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	828
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	499
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	828
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	499
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	1,692



HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	3,509
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	3,618
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	3,509
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	29,823
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	35,081
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	701
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	701
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	11,240
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	22,439
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	528
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	724
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	9,588
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	18,984
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	17,536
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	17,545
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	14,895
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV	14,920



	Alternative TPT Regimen, Life-long ART, New, Positive	
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	240
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	282
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	5
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	5
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	91
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	181
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	5
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	6
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	82
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	156
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	135
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	147
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	121
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	124
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	55,580
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,390
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,239



TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	35,457
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	17,494
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	55,530
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	55,532
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	22,230
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	5,545
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	22,103
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	5,556
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	487
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	10
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	16
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	240
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	220
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	484
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	484
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	194
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	48
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	197
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	45



Implementing Mechanism Details

Mechanism ID: 17965	Mechanism Name: 4Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17965		
Mechanism Name: 4Children		
Prime Partner Name: Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17966	Mechanism Name: Support for International Family Planning and Health Organization 2 (SIFPO 2)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 940,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 940,000	
Funding Source	Funding Amount
GHP-State	940,000



Cross-Cutting Budget Attribution(s)

Condom programming	686,750
Adolescent Girls and Young Women (AGYW)	454,167

Budget Code Information

Mechanism ID:	17966	
Mechanism Name:	Support for International Family Planning and Health	
Prime Partner Name:	Organization 2 (SIFPO 2)	
	Population Services International	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	90,563
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	165,599
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	681,250
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,588
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	18,046
PP_PREV_DSD	Age/sex: 20-24 Male	4,512
PP_PREV_DSD	Age/sex: 20-24 Female	4,512
PP_PREV_DSD	Sum of Age/Sex disaggregates	9,024
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	4,512
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	4,512
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,000
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,420
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	80
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,425
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	1,420
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,425
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	75

Implementing Mechanism Details

Mechanism ID: 17967	Mechanism Name: Comprehensive Mobile
----------------------------	---



	Clinical and Prevention Services (CMCPS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: The Luke Commission	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 742,500	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 742,500	
Funding Source	Funding Amount
GHP-State	742,500

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17967	
Mechanism Name:	Comprehensive Mobile Clinical and Prevention Services (CMCPS)	
Prime Partner Name:	The Luke Commission	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	222,750
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	22,275
Strategic Area	Budget Code	Planned Amount
Care	PDCS	7,425
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	133,650
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	348,975
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	7,425

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,057
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	56
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	56
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	264
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	158
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	578



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	368
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	316
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	150
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	37
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	44
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	2



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	96
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	61
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	470
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	578
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	316
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	578
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	264



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	526
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	264
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	578
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	96
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	96
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	44
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	4

HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	44
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	96
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	9
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	17
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	17
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9



TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	7
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	12
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	588
TX_CURR_DSD	Age/Sex: 15-19 Male	6
TX_CURR_DSD	Age/Sex: 15-19 Female	11
TX_CURR_DSD	Sum of age/sex disaggregates	17
TX_CURR_DSD	Age/Sex: <1	1
TX_CURR_DSD	Age/Sex: <1-9	17
TX_CURR_DSD	Age/Sex: 10-14 Male	8
TX_CURR_DSD	Age/Sex: 10-14 Female	8
TX_CURR_DSD	Age/Sex: 20-24 Male	6
TX_CURR_DSD	Age/Sex: 50+ Male	44
TX_CURR_DSD	Age/Sex: 20-24 Female	28
TX_CURR_DSD	Age/Sex: 50+ Female	61
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	44
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	28



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	44
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	28
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	61
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	44
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	94
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	55
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	120
TX_NEW_DSD	By Age/Sex: 1-9	2
TX_NEW_DSD	By Age/Sex: 10-14 Male	1
TX_NEW_DSD	By Age/Sex: 15-19 Male	2
TX_NEW_DSD	By Age/Sex: 20-24 Male	3
TX_NEW_DSD	By Age/Sex: 50+ Male	7
TX_NEW_DSD	By Age/Sex: 10-14 Female	1
TX_NEW_DSD	By Age/Sex: 15-19 Female	3
TX_NEW_DSD	By Age/Sex: 20-24 Female	8
TX_NEW_DSD	By Age/Sex: 50+ Female	2
TX_NEW_DSD	Sum of Age/Sex disaggregates	27
TX_NEW_DSD	Pregnancy status	58
TX_NEW_DSD	Breastfeeding status	58
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	9
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	12
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	7
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male,	14



	Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	9
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	15
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	8
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	15
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	581
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	17
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	221
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	17
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	325

Implementing Mechanism Details

Mechanism ID: 17972	Mechanism Name: Measure Evaluation Phase IV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17972 Mechanism Name: Measure Evaluation Phase IV Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18169	Mechanism Name: CIHTC Follow-on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,638,471	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,638,471	
Funding Source	Funding Amount
GHP-State	3,638,471

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18169		
Mechanism Name: CIHTC Follow-on		
Prime Partner Name: Population Services International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,030,557
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,492,516
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,115,398
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	26,261
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	336
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	336
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	320
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	192
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	16



	15-19, Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	704
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	448
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	385
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	15
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	837
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	405
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	406
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	430
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	72
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	259
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24,	949



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	158
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	604
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	98
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	516
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	85
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	18
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	1,012
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	172
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	167
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	220
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	132
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	481
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	79
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	306



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	51
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	263
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: <1, Negative	7
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	419
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	576
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	702
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	384
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	702
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	321
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	643
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	51



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	321
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	702
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	777
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	127
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	951
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	160
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	516
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	85
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	951
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	160
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	432
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	864
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	141
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49,	432



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	951
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	160
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	394
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	483
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	263
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	483
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	79
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	220
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	437
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	220
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	35



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	483
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	79
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,763
TX_CURR_DSD	Age/Sex: 15-19 Male	17
TX_CURR_DSD	Age/Sex: 15-19 Female	33
TX_CURR_DSD	Sum of age/sex disaggregates	50
TX_CURR_DSD	Age/Sex: <1	3
TX_CURR_DSD	Age/Sex: <1-9	52
TX_CURR_DSD	Age/Sex: 10-14 Male	25
TX_CURR_DSD	Age/Sex: 10-14 Female	25
TX_CURR_DSD	Age/Sex: 20-24 Male	17
TX_CURR_DSD	Age/Sex: 50+ Male	133
TX_CURR_DSD	Age/Sex: 20-24 Female	83
TX_CURR_DSD	Age/Sex: 50+ Female	182
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	133
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	83
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	133
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	83
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	182
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	133
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	282
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male,	166



	Positive	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	360
TX_NEW_DSD	By Age/Sex: <1	1
TX_NEW_DSD	By Age/Sex: 1-9	5
TX_NEW_DSD	By Age/Sex: 10-14 Male	3
TX_NEW_DSD	By Age/Sex: 15-19 Male	7
TX_NEW_DSD	By Age/Sex: 20-24 Male	10
TX_NEW_DSD	By Age/Sex: 50+ Male	21
TX_NEW_DSD	By Age/Sex: 10-14 Female	3
TX_NEW_DSD	By Age/Sex: 15-19 Female	10
TX_NEW_DSD	By Age/Sex: 20-24 Female	24
TX_NEW_DSD	By Age/Sex: 50+ Female	7
TX_NEW_DSD	Sum of Age/Sex disaggregates	85
TX_NEW_DSD	Pregnancy status	175
TX_NEW_DSD	Breastfeeding status	175
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	28
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	35
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	21
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	42
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	28
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	45
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	24
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	45
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral	1,743

	load result documented in the patient medical record and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	52
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	662
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	52
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	976
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	380
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	404
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	190
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	190
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	202
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	202
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	121
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14,	239



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	121
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	121
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	121
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	121
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	361
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	361
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	361
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	361
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	361
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	361
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	361



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	361
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	361
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	361
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	361
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	1,175
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	2,529
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	2,529
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	2,609

Implementing Mechanism Details

Mechanism ID: 18250	Mechanism Name: WHO/AFRO Disease Control
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: WHO/AFRO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 450,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 450,000	
Funding Source	Funding Amount
GHP-State	450,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	450,000
----------------------------	---------

Budget Code Information

Mechanism ID: 18250		
Mechanism Name: WHO/AFRO Disease Control		
Prime Partner Name: WHO/AFRO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	450,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18272	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18329	Mechanism Name: Strengthening Health Information Systems (SHIS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Institute for Health Measurement	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,213,504	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,213,504	
Funding Source	Funding Amount
GHP-State	2,213,504

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18329		
Mechanism Name: Strengthening Health Information Systems (SHIS)		
Prime Partner Name: Institute for Health Measurement		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	837,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	93,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,283,504
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18331	Mechanism Name: Global Health Supply Chain - Procurement and Supply Chain Management (GHSC-PSM)
----------------------------	--



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18331	
Mechanism Name:	Global Health Supply Chain - Procurement and Supply Chain Management (GHSC-PSM)	
Prime Partner Name:	Global Health Supply Chain Program	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	552,294
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	1,306,218
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18387	Mechanism Name: FHI 360 Linkages for Care
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,530,187	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,530,187	
Funding Source	Funding Amount
GHP-State	1,530,187

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	22,000
Focus Area:	Changing harmful gender norms and promoting



	positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	813,868
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	716,319
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

Mechanism ID:	18387
Mechanism Name:	FHI 360 Linkages for Care



Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	933,891
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	336,709
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	259,587
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	990
PrEP_NEW_DSD	Male 15-19	60
PrEP_NEW_DSD	Male 20-24	69
PrEP_NEW_DSD	Female 15-19	99
PrEP_NEW_DSD	Female 20-24	109
PrEP_NEW_DSD	FSW	133



PrEP_NEW_DSD	MSM	133
PrEP_NEW_DSD	TG	133
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	109
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	69
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	99
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	60
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	109
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	60
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	99
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	49
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	133
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	12,776
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,027
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,749
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,188
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	428
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	63
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	54



	15-19, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	517
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	73
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	167
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	118
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	13
HTC_TST_DSD	By Key Population: FSW, Negative	1,697
HTC_TST_DSD	By Key Population: FSW, Positive	237
HTC_TST_DSD	By Key Population: MSM, Negative	1,100
HTC_TST_DSD	By Key Population: MSM, Positive	132
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	339
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	167
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	257
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	167
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	16



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	178
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	167
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	277
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	80
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	80
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	240
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	400
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	240
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	400
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	240
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	400
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	240
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	400
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	240



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	400
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	240
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	400
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	240
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	400
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	240
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	400
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	240
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	400
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	240
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	400
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	240
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	800
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	1,613
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	1,613
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	1,662



Implementing Mechanism Details

Mechanism ID: 18598	Mechanism Name: Project SOAR
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 400,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	400,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18598	
Mechanism Name:	Project SOAR	
Prime Partner Name:	Population Council	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	200,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	200,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18599	Mechanism Name: Reducing Infection through Support and Education (RISE II)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: mother2mothers organisation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)



Water	15,000
-------	--------

Budget Code Information

Mechanism ID: 18599		
Mechanism Name: Reducing Infection through Support and Education (RISE II)		
Prime Partner Name: mother2mothers organisation		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	383,351
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	434,632
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	407,061
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	22,698

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received	4,488



	ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,991
PMTCT_ART_DSD	New on ART	2,008
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,480
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,991
PMTCT_STAT_DSD	Number of new ANC and L&D clients	15,319
PMTCT_STAT_DSD	By Age (Denominator): 10-14	122
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,284
PMTCT_STAT_DSD	By Age (Denominator): 20-24	4,315
PMTCT_STAT_DSD	By Number of known positives: 10-14	9
PMTCT_STAT_DSD	By Number of known positives: 15-19	541
PMTCT_STAT_DSD	By Number of known positives: 20-24	971
PMTCT_STAT_DSD	By Number of new positives: 10-14	8
PMTCT_STAT_DSD	By Number of new positives: 15-19	207
PMTCT_STAT_DSD	By Number of new positives: 20-24	262
PMTCT_STAT_DSD	By Number of new negative: 10-14	92
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,476
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,885
PMTCT_STAT_DSD	By Age (Numerator): 10-14	131
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,212
PMTCT_STAT_DSD	By Age (Numerator): 20-24	3,119
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	4,633
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	2,287
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	1,525
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	153
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	963
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	2,902



	25-29, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	394
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	496
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	1,941
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	261
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	334
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,162
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	160
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	30
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	200
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	19
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	4,255
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	2,694
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,646
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	254
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,500
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,599
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	901
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,500

Implementing Mechanism Details



Mechanism ID: 18600	Mechanism Name: Triple R (ready, resourceful, risk aware): OVC, Adolescent Girls, and Young Women
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 9,886,365	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 9,886,365	
Funding Source	Funding Amount
GHP-State	8,528,555
GHP-USAID	1,357,810

Cross-Cutting Budget Attribution(s)

Gender: GBV	600,728
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Gender: Gender Equality	105,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Key Populations: FSW	14,580
Focus Area:	Training of health workers and community outreach workers



Food and Nutrition: Policy, Tools, and Service Delivery	5,000
Education	60,000
Adolescent Girls and Young Women (AGYW)	4,345,450
Economic Strengthening	100,000

Budget Code Information

Mechanism ID:	18600	
Mechanism Name:	Triple R (ready, resourceful, risk aware): OVC, Adolescent Girls, and Young Women	
Prime Partner Name:	Pact, Inc.	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	6,593,634
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	802,407
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	729,907
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	128,460
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,631,957
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	45,041
PP_PREV_DSD	Age/sex: 15-19 Male	2,254
PP_PREV_DSD	Age/sex: 10-14 Female	9,009
PP_PREV_DSD	Age/sex: 15-19 Female	13,513
PP_PREV_DSD	Age/sex: 20-24 Female	11,262
PP_PREV_DSD	Sum of Age/Sex disaggregates	36,038
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	9,009
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,813
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	390
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,913
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	2,679
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	2,679
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	56
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	66,026



OVC_SERV_DSD	Age/Sex: 10-14 Male	9,509
OVC_SERV_DSD	Age/Sex: 15-17 Male	9,509
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,322
OVC_SERV_DSD	By: Age/sex: Male 25+	1,322
OVC_SERV_DSD	Age/Sex: 10-14 Female	11,620
OVC_SERV_DSD	Age/Sex: 15-17 Female	11,620
OVC_SERV_DSD	By: Age/sex: 18-24 Female	5,281
OVC_SERV_DSD	By: Age/sex: 25+ Female	5,281
OVC_SERV_DSD	Sum of Age/Sex disaggregates	42,258
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	3,088
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	2,796
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	2,389
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	1,838
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	7,584
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,157
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1,371
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	15,166
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	11,972
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	12,341
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	161
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	1,770



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	10,172
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	10,481
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	161
OVC_SERV_DSD	Age/Sex: <1	2,642
OVC_SERV_DSD	Age/Sex: 1-9	7,924
OVC_SERV_DSD	Program Completion: Active	66,026
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	41,269
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	66,026

Implementing Mechanism Details

Mechanism ID: 18601	Mechanism Name: HIV Response Coordination, Community Capacity and Communications (HC4) Breakthrough Action
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Center for Communication Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,350,391	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,350,391	
Funding Source	Funding Amount
GHP-State	2,350,391



Cross-Cutting Budget Attribution(s)

Gender: GBV	180,076
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Adolescent Girls and Young Women (AGYW)	210,078

Budget Code Information

Mechanism ID:	18601	
Mechanism Name:	HIV Response Coordination, Community Capacity and Communications (HC4) Breakthrough Action	
Prime Partner Name:	Johns Hopkins University Center for Communication Programs	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	810,078
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	105,039
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	262,598
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	472,676
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	700,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	41,474
PP_PREV_DSD	Age/sex: 15-19 Male	6,219
PP_PREV_DSD	Age/sex: 20-24 Male	10,370
PP_PREV_DSD	Sum of Age/Sex disaggregates	16,589
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	10,370
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	10,370
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	4,149

Implementing Mechanism Details

Mechanism ID: 18602	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70329	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70330	Mechanism Name: Technical Support for PEPFAR Programs in Southern Africa
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine Children's Foundation Malawi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	70330	
Mechanism Name:	Technical Support for PEPFAR Programs in Southern Africa	
Prime Partner Name:	Baylor College of Medicine Children's Foundation Malawi	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	599,500
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	310,620
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	775,500

Approved



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70331	TBD: Yes
REDACTED	



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services			82,433	82,433	0	82,433
ICASS			595,404	595,404	0	595,404
Institutional Contractors			350,000	350,000	0	350,000
Management Meetings/Professional Development			33,532	33,532	0	33,532
Non-ICASS Administrative Costs			335,639	335,639	0	335,639
Staff Program Travel			62,975	62,975	0	62,975
USG Staff Salaries and Benefits - Internationally Recruited			1,445,318	1,445,318	0	1,445,318
USG Staff Salaries and Benefits - Locally Recruited		0	603,377	603,377	0	603,377



Total	0	0	3,508,678	3,508,678	0	3,508,678
--------------	----------	----------	------------------	------------------	----------	------------------

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		0		0	33,000	33,000
Non-ICASS Motor Vehicles		0		0	60,000	60,000
Staff Program Travel				0	30,000	30,000
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		41,939		41,939	91,061	133,000
Total	0	41,939	0	41,939	214,061	256,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and
--------------------------------------	------------	------------------	------------------	-----------------------------	-------------------------	--------------------------------------



						Applied Pipeline Amount
Capital Security Cost Sharing		224,017		224,017	0	224,017
Computers/IT Services		60,000		60,000	0	60,000
ICASS		464,620		464,620	0	464,620
Institutional Contractors		480,380		480,380	0	480,380
Management Meetings/Professional Development		12,000		12,000	0	12,000
Non-ICASS Administrative Costs		42,225		42,225	0	42,225
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel	0	213,189		213,189	0	213,189
USG Staff Salaries and Benefits - Internationally Recruited	487,500	560,106		1,047,606	0	1,047,606
USG Staff Salaries and Benefits - Locally Recruited	0	739,416		739,416	0	739,416
Total	487,500	2,795,953	0	3,283,453	0	3,283,453



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		132,700		132,700	0	132,700
Computers/IT Services		0		0	0	0
ICASS		122,485		122,485	0	122,485
Institutional Contractors		0		0	0	0
Management Meetings/Professional Development		18,600		18,600	0	18,600
Non-ICASS Administrative Costs		16,420		16,420	0	16,420
Staff Program Travel		74,171		74,171	0	74,171
USG Staff Salaries and Benefits - Internationally Recruited		435,296		435,296	0	435,296
USG Staff Salaries and Benefits - Locally Recruited		275,257		275,257	0	275,257
Total	0	1,074,929	0	1,074,929	0	1,074,929



U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Non-ICASS Administrative Costs		80,000		80,000	0	80,000
Peace Corps Volunteer Costs		580,786		580,786	219,214	800,000
Staff Program Travel		6,000		6,000	0	6,000
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		179,000		179,000	0	179,000
Total	0	845,786	0	845,786	219,214	1,065,000